Tucatinib is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer wo have received at least two prior anti-HER2 treatment regimens.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||23/08/2022|
|Rapid review completed||20/09/2022|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tucatinib compared with the current standard of care.|